

Specialty Medication Review Program

Complete this form and fax to:

Medical Specialty Unit
Fax #: 1-800-306-0188
Phone #: 1-800-499-1275

If you are not **buying and billing** this medication, indicate which specialty pharmacy will be used:

<input type="checkbox"/> Accredo Health Fax: 1-888-773-7386 Phone: 1-866-413-4137	<input type="checkbox"/> Walgreens Specialty Pharmacy Fax: 1-866-435-2173 Phone: 1-866-435-2171	<input type="checkbox"/> Noble Fax: 1-888-842-3977 Phone: 1-888-843-2040
--	--	---

Complete ALL the following Patient/Prescriber Information: (Please Print)

Patient Information					
Patient Name:			Patient Phone #: ()		
Patient ID #:			Patient Birthdate:		
List Patient Allergy (If Any):					
Prescriber Information					
Prescriber Name:			Prescriber Specialty:		
Prescriber Address:					
Prescriber Phone #:			Prescriber Fax #:		
Prescriber NPI #:			Office Contact:		Extension:
Location of Infusion: <input type="checkbox"/> Prescriber office <input type="checkbox"/> Home/Homecare agency: _____ <input type="checkbox"/> Outpatient facility <input type="checkbox"/> Other: _____					
Servicing Prescriber NPI (if different from the ordering prescriber):					
Provide address of infusion location above for medication shipping:					
Medication/Medical and Dispensing Information					
Medication (HCP/CS)	Dose	Frequency	Height	Weight (lbs./kgs)	Procedure Code
Vyvgart (J9332)					
Vyvgart Hytrulo (J9334)					
Diagnosis/ICD-10:					
Is this request for a: <input type="checkbox"/> New Start OR <input type="checkbox"/> Continuation of Therapy (Recertification) Start date: _____					
Questions/Indications for Medical Necessity					
See the Rare Diseases Clinical Prior Authorization Policy (Pharmacy-98) for full Prior Authorization criteria					
Select One of The Following Diagnoses:					
<input type="checkbox"/> Generalized Myasthenia Gravis (gMG)			<input type="checkbox"/> Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)		
<input type="checkbox"/> Other: _____					
Generalized Myasthenia Gravis					
1. What is the patient's Myasthenia Gravis Foundation of America (MGFA) clinical classification?					
<input type="checkbox"/> Class I		<input type="checkbox"/> Class II		<input type="checkbox"/> Class III	
<input type="checkbox"/> Class IV		<input type="checkbox"/> Class V		<input type="checkbox"/> Unknown	
2. Is the patient anti-acetylcholine receptor (AChR) antibody positive?					<input type="checkbox"/> Yes <input type="checkbox"/> No
3. Does the patient have a documented baseline Myasthenia Gravis Activities of Daily Living (MG-ADL) score at least 5?					<input type="checkbox"/> Yes <input type="checkbox"/> No
4. Has the patient had serious side effects or drug failure to corticosteroids for at least 3 months of treatment					<input type="checkbox"/> Yes <input type="checkbox"/> No
5. Has the patient had serious side effects or drug failure to non-steroidal immunosuppressive therapy (i.e., azathioprine, mycophenolate mofetil, cyclosporine) for at least 6 months of treatment					<input type="checkbox"/> Yes <input type="checkbox"/> No
6. Will Vyvgart/Vyvgart Hytrulo be used in combination with Rystiggo, Soliris, Ultomiris, intravenous immunoglobulin (IVIG) for chronic use, or rituximab-containing products?					<input type="checkbox"/> Yes <input type="checkbox"/> No
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)- For Vyvgart Hytrulo only					
1. Does the patient have confirmed CIDP with supporting documentation (e.g., electrodiagnostic testing, clinical assessment, nerve biopsy)					<input type="checkbox"/> Yes <input type="checkbox"/> No
2. Has the patient had serious side effects or drug failure to corticosteroids treatment					<input type="checkbox"/> Yes <input type="checkbox"/> No
3. Has the patient had serious side effects or drug failure to intravenous or subcutaneous immune globulin (IVIG or SCIG) treatment in the past 12 month					<input type="checkbox"/> Yes <input type="checkbox"/> No
4. For recertification requests only. Is there documentation of clinical improvement on an objective scale? (e.g., (e.g., Rankin, Modified Rankin, Medical Research Council (MRC), Inflammatory Rasch-built Overall Disability Scale (I-RODS), Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale)					<input type="checkbox"/> Yes <input type="checkbox"/> No
5. Will Vyvgart Hytrulo be used in combination with Rystiggo, Soliris, Ultomiris, intravenous immunoglobulin (IVIG) for chronic use, or rituximab-containing products?					<input type="checkbox"/> Yes <input type="checkbox"/> No



Vyvgart (efgartigimod alfa-fcab)
Vyvgart Hytrulo (efgartigimod alfa & hyaluronidase-qvfc)
(Health Professional Administered)
Medical Benefit

Provide Other Comments/Clinical Justification:

ATTACH CLINICAL NOTES RELATED TO THIS REQUEST. IF DOCUMENTATION IS NOT PROVIDED, IT MAY DELAY THE REQUEST.

***Prescriber Signature:** _____ **Date:** _____

I certify the above is true and accurate to the best of my knowledge.